Protalix Biotherapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Protalix Biotherapeutics, Inc. on December 13, 2011. The report serves as a current disclosure under Regulation FD regarding an upcoming corporate presentation.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of an event and does not contain financial statements or performance data.
Material Changes
No material changes to financial position or operations are reported in this filing. The document solely announces a scheduled presentation by company leadership.
Guidance, Outlook, and Management Commentary
Dr. David Aviezer, President and Chief Executive Officer, is scheduled to present at the Oppenheimer 22nd Annual Healthcare Conference. The presentation is set for Wednesday, December 14, 2011, at 3:55 PM ET at The Waldorf-Astoria Hotel in New York City. The press release accompanying this filing is included as Exhibit 99.1.
Key Facts for Investor Verification
- Verify the date and time of the CEO's presentation at the Oppenheimer Healthcare Conference (December 14, 2011, 3:55 PM ET).
- Review the full text of the press release provided in Exhibit 99.1 for any additional details on the presentation content.
- Note that the information in this 8-K is not deemed "filed" for purposes of Section 18 of the Exchange Act unless expressly referenced in another filing.